{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:35:52Z","timestamp":1792697752182,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:00:00Z","timestamp":1437004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/hr.2015.82","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T06:01:12Z","timestamp":1437026472000},"page":"765-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients"],"prefix":"10.1038","volume":"38","author":[{"given":"Ryuji","family":"Chida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Hisauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Migaku","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"BFhr201582_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-93-6-817","volume":"93","author":"FH Messerli","year":"1980","unstructured":"Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG . Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817\u2013821.","journal-title":"Ann Intern Med"},{"key":"BFhr201582_CR2","first-page":"1501","volume":"27","author":"KC Lin","year":"2000","unstructured":"Lin KC, Lin HY, Chou P . The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501\u20131505.","journal-title":"J Rheumatol"},{"key":"BFhr201582_CR3","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","volume":"283","author":"J Fang","year":"2000","unstructured":"Fang J, Alderman MH . Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404\u20132410.","journal-title":"JAMA"},{"key":"BFhr201582_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/01.HYP.0000150784.92944.9a","volume":"45","author":"J Sundstrom","year":"2005","unstructured":"Sundstrom J, Sullivan L, D\u2019Agostino RB . Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28\u201333.","journal-title":"Hypertension"},{"key":"BFhr201582_CR5","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson R . Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811\u20131821.","journal-title":"N Engl J Med"},{"key":"BFhr201582_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2458-4-9","volume":"4","author":"D Conen","year":"2004","unstructured":"Conen D, Wietlisbach V, Bovet P . Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4: 9.","journal-title":"BMC Public Health"},{"key":"BFhr201582_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.amjmed.2010.03.027","volume":"123","author":"V Bhole","year":"2010","unstructured":"Bhole V, Choi JW, Kim SW, de Vera M, Choi H . Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010; 123: 957\u2013961.","journal-title":"Am J Med"},{"key":"BFhr201582_CR8","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.2337\/db09-0014","volume":"8","author":"P Hovind","year":"2009","unstructured":"Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH . Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 8: 1668\u20131671.","journal-title":"Diabetes"},{"key":"BFhr201582_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","volume":"56","author":"G Bellomo","year":"2010","unstructured":"Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M . Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56: 264\u2013272.","journal-title":"Am J Kidney Dis"},{"key":"BFhr201582_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ajkd.2010.01.024","volume":"56","author":"CP Wen","year":"2010","unstructured":"Wen CP, David Cheng TY, Chan HT . Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 2010; 56: 273\u2013288.","journal-title":"Am J Kidney Dis"},{"key":"BFhr201582_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00005344-199608000-00012","volume":"28","author":"JP Fauvel","year":"1996","unstructured":"Fauvel JP, Velon S, Berra N, Pozet N, Madonna O, Zech P . Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996; 28: 259\u2013263.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr201582_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/hr.2013.112","volume":"37","author":"EJ Kim","year":"2014","unstructured":"Kim EJ, Song WH, Lee JU, Shin MS, Lee S, Kim BO . Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study. Hypertens Res 2014; 37: 50\u201356.","journal-title":"Hypertens Res"},{"key":"BFhr201582_CR13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0149-2918(00)83062-3","volume":"22","author":"AJ Manolis","year":"2000","unstructured":"Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ . Effects of losartan and candesartan monotherapy and losartan\/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension: Losartan Trial Investigators. Clin Ther 2000; 22: 1186\u20131203.","journal-title":"Clin Ther"},{"key":"BFhr201582_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0149-2918(01)80099-0","volume":"23","author":"WJ Elliott","year":"2001","unstructured":"Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK . Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23: 1166\u20131179.","journal-title":"Clin Ther"},{"key":"BFhr201582_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1254\/jphs.10064SC","volume":"114","author":"M Nakamura","year":"2010","unstructured":"Nakamura M, Anzai N, Jutabha P, Sato H, Sakurai H, Ichida K . Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci 2010; 114: 115\u2013118.","journal-title":"J Pharmacol Sci"},{"key":"BFhr201582_CR16","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","volume":"19","author":"G Wurzner","year":"2001","unstructured":"Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR . Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855\u20131860.","journal-title":"J Hypertens"},{"key":"BFhr201582_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/hr.2013.3","volume":"26","author":"I Taguchi","year":"2013","unstructured":"Taguchi I, Toyoda S, Takano K, Arikawa T, Kikuchi M, Ogawa M, Abe S, Node K, Inoue T . Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and anti-oxidative effects in patients with high-risk hypertension. Hypertens Res 2013; 26: 608\u2013613.","journal-title":"Hypertens Res"},{"key":"BFhr201582_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1475-2840-8-5","volume":"8","author":"K Node","year":"2009","unstructured":"Node K, Inoue T, Boyko V . Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment. Cardiovasc Diabetol 2009; 8: 5.","journal-title":"Cardiovasc Diabetol"},{"key":"BFhr201582_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jjcc.2008.11.010","volume":"53","author":"K Matsuo","year":"2009","unstructured":"Matsuo K, Inoue T, Node K . Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease. J Cardiol 2009; 53: 232\u2013239.","journal-title":"J Cardiol"},{"key":"BFhr201582_CR20","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/clinchem\/45.12.2136","volume":"45","author":"N Rifai","year":"1999","unstructured":"Rifai N, Tracy RP, Ridker PM . Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136\u20132141.","journal-title":"Clin Chem"},{"key":"BFhr201582_CR21","first-page":"127","volume":"18","author":"MR Cearone","year":"1999","unstructured":"Cearone MR, Belcalo G, Carratelli M . A simple test to monitor oxidative stress. Int Angiol 1999; 18: 127\u2013130.","journal-title":"Int Angiol"},{"key":"BFhr201582_CR22","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1093\/jn\/131.12.3208","volume":"131","author":"U Cornelli","year":"2001","unstructured":"Cornelli U, Terranova R, Luca S, Cornelli S, Alberti A . Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001; 131: 3208\u20133211.","journal-title":"J Nutr"},{"key":"BFhr201582_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/172460080401900312","volume":"19","author":"A Cavalleri","year":"2004","unstructured":"Cavalleri A, Colombo C, Venturelli E . Evaluation of reactive oxygen metabolites in frozen serum samples. Effect of storage and repeated thawing. Int J Biol Markers 2004; 19: 250\u2013253.","journal-title":"Int J Biol Markers"},{"key":"BFhr201582_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0300-483X(00)00231-6","volume":"149","author":"JP Kehrer","year":"2000","unstructured":"Kehrer JP . The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000; 149: 43\u201355.","journal-title":"Toxicology"},{"key":"BFhr201582_CR25","first-page":"41","volume":"4","author":"M Burnier","year":"1996","unstructured":"Burnier M, Brunner HR . Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nephrol 1996; 4: 41\u201346.","journal-title":"Exp Nephrol"},{"key":"BFhr201582_CR26","first-page":"186","volume":"60","author":"Y Nindita","year":"2010","unstructured":"Nindita Y, Hamada T, Bahrudin U . Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA. Arzneimittelforschung 2010; 60: 186\u2013188.","journal-title":"Arzneimittelforschung"},{"key":"BFhr201582_CR27","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/ajh.2008.245","volume":"21","author":"T Hamada","year":"2008","unstructured":"Hamada T, Ichida K, Hosoyamada M . Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21: 1157\u20131162.","journal-title":"Am J Hypertens"},{"key":"BFhr201582_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","volume":"58","author":"Y Miao","year":"2011","unstructured":"Miao Y, Ottenbros SA, Laverman GD . Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post-hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. J Hypertens 2011; 58: 2\u20137.","journal-title":"J Hypertens"},{"key":"BFhr201582_CR29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870\u2013878.","journal-title":"N Engl J Med"},{"key":"BFhr201582_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR . Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851\u2013860.","journal-title":"N Engl J Med"},{"key":"BFhr201582_CR31","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.2174\/138161205774913255","volume":"11","author":"GK Glantzounis","year":"2005","unstructured":"Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA . Uric acid and oxidative stress. Curr Pharm Design 2005; 11: 4145\u20134151.","journal-title":"Curr Pharm Design"},{"key":"BFhr201582_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0021-9150(99)00214-2","volume":"148","author":"FJ Nieto","year":"2000","unstructured":"Nieto FJ, Iribarren C, Gross MD, Comstock GW, Gutler RG . Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131\u2013139.","journal-title":"Atherosclerosis"},{"key":"BFhr201582_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0021-9150(96)06064-9","volume":"130","author":"K Nyyssonen","year":"1997","unstructured":"Nyyssonen K, Porkkala-Sarataho E, Kaikkonen J . Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis 1997; 130: 223\u2013233.","journal-title":"Atherosclerosis"},{"key":"BFhr201582_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/CS20030149","volume":"105","author":"WS Waring","year":"2003","unstructured":"Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SRJ . Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci 2003; 105: 425\u2013430.","journal-title":"Clin Sci"},{"key":"BFhr201582_CR35","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1089\/ars.2005.7.1040","volume":"7","author":"JL Evans","year":"2005","unstructured":"Evans JL, Maddux BA, Goldfine ID . The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7: 1040\u20131052.","journal-title":"Antioxid Redox Signal"},{"key":"BFhr201582_CR36","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/ajh.2008.289","volume":"21","author":"K Tsukimori","year":"2008","unstructured":"Tsukimori K, Yoshitomi T, Morokuma S, Fukushima K, Wake N . Serum uric acid levels correlate with plasma hydrogen peroxide and protein carbonyl levels in preeclampsia. Am J Hypertens 2008; 21: 1343\u20131346.","journal-title":"Am J Hypertens"},{"key":"BFhr201582_CR37","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.2337\/diacare.28.7.1690","volume":"28","author":"F Chiarelli","year":"2005","unstructured":"Chiarelli F, Marzio D, Santilli F, Mohn A, Blasetti A, Cipollone F, Mezzetti A, Verrotti A . Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabetes Care 2005; 28: 1690\u20131697.","journal-title":"Diabetes Care"},{"key":"BFhr201582_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/hr.2012.196","volume":"36","author":"H Takagi","year":"2013","unstructured":"Takagi H, Mizuno Y, Yamamoto H, Goto S, Umemoto T . All-Literature Investigation of Cardiovascular Evidence Group. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 2013; 36: 368\u2013373.","journal-title":"Hypertens Res"},{"key":"BFhr201582_CR39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1523-1755.2004.00484.x","volume":"65","author":"A Hoieggen","year":"2004","unstructured":"Hoieggen A, Alderman MH, Kjeldsen SE . The impact of serum uric acid on cardiovascular outcomes in the LIFE Study. Kidney Int 2004; 65: 1041\u20131049.","journal-title":"Kidney Int"},{"key":"BFhr201582_CR40","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"SC Smith","year":"2011","unstructured":"Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA . AHA\/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458\u20132473.","journal-title":"Circulation"},{"key":"BFhr201582_CR41","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1161\/01.ATV.0000161274.87407.26","volume":"25","author":"N Ishizaka","year":"2005","unstructured":"Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M . Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25: 1038\u20131044.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr201582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201582","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:16:03Z","timestamp":1684430163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFhr201582"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.82","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]},"assertion":[{"value":"4 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}